PARP1 and lung adenocarcinoma: Accordingly, the main objectives in the current investigation were to assess, in lung adenocarcinoma tumors of BALB/c mice treated with rucaparib, the following parameters: (1) PARP activity levels, (2) PARP-1 and PARP-2 protein expression, (3) DNA damage, (4) cell proliferation, (5) protein oxidation levels, and (6) antioxidants.